Cargando…
BCL-2 is dispensable for thrombopoiesis and platelet survival
Navitoclax (ABT-263), an inhibitor of the pro-survival BCL-2 family proteins BCL-2, BCL-X(L) and BCL-W, has shown clinical efficacy in certain BCL-2-dependent haematological cancers, but causes dose-limiting thrombocytopaenia. The latter effect is caused by Navitoclax directly inducing the apoptotic...
Autores principales: | Debrincat, M A, Pleines, I, Lebois, M, Lane, R M, Holmes, M L, Corbin, J, Vandenberg, C J, Alexander, W S, Ng, A P, Strasser, A, Bouillet, P, Sola-Visner, M, Kile, B T, Josefsson, E C |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group
2015
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4650559/ https://www.ncbi.nlm.nih.gov/pubmed/25880088 http://dx.doi.org/10.1038/cddis.2015.97 |
Ejemplares similares
-
Bcl-2 family member Bcl-G is not a proapoptotic protein
por: Giam, M, et al.
Publicado: (2012) -
Autoantibody-mediated desialylation impairs human thrombopoiesis and platelet lifespan
por: Marini, Irene, et al.
Publicado: (2019) -
Detection of Bcl-2 family member Bcl-G in mouse tissues using new monoclonal antibodies
por: Giam, M, et al.
Publicado: (2012) -
Physiological restraint of Bak by Bcl-x(L) is essential for cell survival
por: Lee, Erinna F., et al.
Publicado: (2016) -
The necroptotic cell death pathway operates in megakaryocytes, but not in platelet synthesis
por: Moujalled, Diane, et al.
Publicado: (2021)